Rheumatoid arthritis is entering a new competitive phase, where biosimilar pressure, oral therapies and next-generation immunology are reshaping how value is created and sustained.

In this article, we examine how a once-biologics-led market is becoming more complex, with pricing, access, and pipeline depth now as important as clinical performance. More than continued growth; it signals a structural shift in how the RA market will evolve.

For a deeper analysis, request sample pages from Visiongain’s Rheumatoid Arthritis Drugs Market Report 2026–2036, which examines how competition, pricing and innovation are reshaping the market over the next decade.

Visiongain Top Takeaways

• A market shifting structurally, not just growing; biologics dominance is giving way to a more complex, multi-driver landscape
• Biosimilars are resetting the commercial model; compressing revenues while expanding access and total patient volume
• Oral therapies are broadening adoption; convenience and adherence are becoming as important as efficacy
• Pipeline depth is the new differentiator; next-generation mechanisms are targeting underserved, refractory populations
• Access and pricing are now strategic levers; reimbursement alignment and real-world value are critical to market share

The RA Market Is Moving Beyond Its Biologics-Led Model

For much of the past decade, the rheumatoid arthritis (RA) market has been defined by biologics, both in terms of clinical progress and commercial value. That framing, however, is becoming increasingly outdated as multiple forces begin to reshape how the market functions.

According to Visiongain’s latest research, the global RA drug market is expected to surpass US$58.60 billion by 2037, growing at a CAGR of 4.1% through 2036. The key issue, however, is no longer simply growth, but how value is being redistributed across a more complex and competitive landscape.

Biosimilars Are Reshaping, Not Just Eroding, the Market

Biologics developed by companies such as AbbVie, Pfizer and Amgen established a model that combined strong efficacy with premium pricing and long product lifecycles. That model is now under sustained pressure from biosimilar competition.

While much of the focus has been on price erosion and revenue decline, this captures only part of the picture. Biosimilars are also increasing access to treatment, enabling earlier intervention and expanding the overall treated population.

The result is not simply a contraction of value, but a redistribution of it.

Visiongain Insight: Biosimilars are best understood as a structural shift in the RA market, where competitive advantage increasingly depends on scale, pricing strategy, and lifecycle management rather than brand exclusivity.

Oral Therapies Are Expanding the Addressable Market

JAK inhibitors, including those developed by Eli Lilly and Company and AbbVie, represent a meaningful evolution in RA treatment, particularly in terms of convenience and patient adherence.

Although safety concerns, especially in European markets, have moderated their uptake, recent developments in formulation and real-world evidence are beginning to stabilise their position within treatment pathways.

What is becoming clearer is that treatment decisions are no longer driven solely by efficacy. Convenience, persistence, and patient preference are playing a more prominent role, particularly in earlier lines of therapy.

Visiongain Insight: Oral therapies are not displacing biologics outright, but they are broadening the market by lowering barriers to initiation and improving long-term adherence.

The Pipeline Is Moving Beyond Established Mechanisms

At the same time, the development pipeline is becoming both broader and more diverse. More than 75 companies are advancing over 80 candidates, many of which move beyond established TNF and JAK pathways.

This includes emerging approaches such as CAR-T cell therapy, PD-1 targeting, and other novel immune-modulating strategies, alongside continued investment from major pharmaceutical groups.

While not all of these approaches will reach commercialisation, they collectively indicate a shift away from incremental innovation toward more differentiated and, in some cases, potentially transformative therapies.

Visiongain Insight: In this environment, companies with depth across multiple mechanisms are likely to be better positioned than those reliant on a single class, particularly in addressing refractory and biologic-resistant patient populations.

Access and Reimbursement Are Becoming Central to Competition

Beyond innovation, access dynamics are playing an increasingly important role in shaping the market. Expanded reimbursement frameworks and subsidy programmes are making biologic therapies more widely available, particularly in regions where cost has historically limited uptake.

This is driving higher treatment volumes, but also intensifying competition across therapeutic classes, as payers place greater emphasis on comparative value and long-term outcomes.

Visiongain Insight: Commercial success in RA will increasingly depend on aligning pricing strategies with reimbursement structures, while demonstrating measurable real-world value.

A Market Defined by Multiple Competitive Fronts

Taken together, these trends point to a market that is no longer defined by a single dominant therapy class. Instead, competition is emerging across several interconnected areas, including biosimilar scale, oral therapy adoption, and next-generation innovation.

Companies that can operate effectively across these areas, rather than relying on a single legacy product, are likely to be better positioned as the market continues to evolve.

What This Means Going Forward

The RA market will continue to grow over the coming decade, but the underlying structure of that growth is changing. Value is being redistributed across a broader set of players, technologies, and access models, making the competitive environment more complex than in previous cycles.

From Visiongain

Detailed market forecasts, competitive analysis, and sector reports help you make clear, future-proof strategic choices across R&D, manufacturing, supply chain, and commercial execution.

Explore the latest strategic market reports:

• Rheumatoid Arthritis Drugs Market Report 2026-2036
• Anti-obesity Drugs Market Report 2026-2036
• Longevity Market Report 2026-2036
• Alzheimer’s Therapeutics Market Report 2026-2036
• Ophthalmic Drugs Market Report 2026-2036

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com